CytomX Therapeutics (CTMX) Interest & Investment Income (2014 - 2026)

CytomX Therapeutics has reported Interest & Investment Income for 13 years, with the latest figure at $1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Interest & Investment Income rose 56.02% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2026 stood at $5.7 million (down 2.65% YoY), and the FY2025 full-year result was $5.2 million, down 27.05% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $1.5 million, up from $1.5 million in the prior quarter.
• The five-year high for Interest & Investment Income was $2.7 million in Q3 2023, with the low at $68000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $1.5 million across 5 years, with a median of $1.5 million in 2026.
• Annual changes were most pronounced in 2023 — Interest & Investment Income surged 3322.06% — and 2025, when it tumbled 56.47%.
• CytomX Therapeutics' Interest & Investment Income stood at $732000.0 in 2022, then jumped by 241.94% to $2.5 million in 2023, then sank by 48.94% to $1.3 million in 2024, then climbed by 15.88% to $1.5 million in 2025, then advanced by 0.61% to $1.5 million in 2026.
• The last three Interest & Investment Income figures came in at $1.5 million (Q1 2026), $1.5 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.